Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antihypertensive agents: - **Losartan** is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, leading to vasodilation and reduced aldosterone secretion. - **Atenolol** is a cardioselective beta-1 adrenergic receptor antagonist (beta-blocker) that reduces heart rate and cardiac output, thereby lowering blood pressure. - **Propranolol** is a non-selective beta adrenergic antagonist (beta-blocker) that blocks both beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and renin release. This specific triple combination does not appear to be available as a single commercial product or fixed-dose formulation. Each component has established use in hypertension management but combining two different beta blockers (atenolol and propranolol) with an ARB like losartan in one regimen is highly unusual in clinical practice due to overlapping mechanisms and increased risk of adverse effects. There are no known brand names or marketed products containing all three ingredients together[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on losartan + atenolol + propranolol.